 During the run-in period, CZP will be administered at 400 mg 2 injections at Wks 0, 2, and 4 and 200 mg with placebo 1 injection placebo, 1 injection CZP at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16. 